Table 1.
Patient characteristics of cohorts I and II.
| Patient characteristics | Cohort I (n = 5,897) |
Cohort II (n = 1,558) |
|---|---|---|
| Age (years) | 48.3 ± 14.2 | 51.8 ± 15.5 |
| Female sex | 2,604 (44.2%) | 697 (44.7%) |
| BMI∗ (kg/m2) | 25.9 (22.8–30.1) | 26.0 (23.2–29.4) |
| Diabetes | 839 (14.2%) | 157 (10.1%) |
| Etiology | ||
| AIH/cholestatic | 482 (8.2%) | 114 (7.3%) |
| ALD | 350 (5.9%) | 145 (9.3%) |
| MASLD | 1,688 (28.6%) | 984 (63.2%) |
| Viral | 3,053 (51.8%) | 280 (18.0%) |
| Other | 324 (5.5%) | 35 (2.2%) |
| LSM (kPa) | 6.9 (5.1–10.9) | 5.8 (4.5–8.8) |
| <6 | 2,187 (37.1%) | 803 (51.5%) |
| 6–9.9 | 2,020 (34.3%) | 433 (27.8%) |
| 10–14.9 | 781 (13.2%) | 149 (9.6%) |
| ≥15 | 909 (15.4%) | 173 (11.1%) |
| LSM ≥10 kPa (cACLD) | 1,690 (28.7%) | 322 (20.7%) |
| LiverRisk score (points) | 6.38 (5.30–8.23) | 6.17 (5.13–7.95) |
| <6 | 2,472 (41.9%) | 716 (46.0%) |
| 6 to <10 | 2,575 (43.7%) | 649 (41.7%) |
| 10 to <15 | 597 (10.1%) | 129 (8.3%) |
| ≥15 | 253 (4.3%) | 64 (4.1%) |
| Platelet count (G/L) | 221 (174–268) | 240 (200–283) |
| AST (U/L) | 35 (25–54) | 33 (26–47) |
| ALT (U/L) | 43 (27–73.0) | 40 (26–65) |
| GGT (U/L) | 52 (25–118) | 59 (28–129) |
| Glucose (mg/dl) | 94 (86–106) | 93 (85–104) |
| Cholesterol (mg/dl) | 177 (151–207) | 199 (169–232) |
| APRI | 0.41 (0.26–0.73) | 0.35 (0.25–0.56) |
| <0.5 | 3,533 (59.9%) | 1,093 (70.2%) |
| 0.5–1.5 | 1,792 (30.4%) | 392 (25.2%) |
| >1.5 | 572 (9.7%) | 73 (4.7%) |
| FIB-4 | 1.19 (0.77–1.90) | 1.11 (0.75–1.70) |
| <1.3 | 3,276 (55.6%) | 925 (59.4%) |
| 1.3–2.67 | 1,741 (29.5%) | 453 (29.1%) |
| >2.67 | 880 (14.9%) | 180 (11.6%) |
AIH, autoimmune hepatitis; ALD, alcohol-related liver disease; ALT, alanine aminotransferase; APRI, aspartate aminotransferase-to-platelet ratio index; AST, aspartate aminotransferase; FIB-4, fibrosis-4; GGT, gamma-glutamyl transferase; LSM, liver stiffness measurement; MASLD, metabolic dysfunction-associated steatotic liver disease.
∗
Missing in 603 (10.2%) and 37 (2.4%) patients in cohorts I and II, respectively.